AzTrials
AzTrials

Diabetic NephropathySWIDINEPNCT03407989

SWIDINEP a Swiss Diabetic Nephropathy Cohort

An observational study of Diabetic Nephropathy, run by Centre Hospitalier Universitaire Vaudois at 1 site in Switzerland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

With our SWIDINEP cohort, we propose to explore the relationship between vascular risk markers and renal function decline in CKD stage 1-5. In order to realize these goals, we intend to recruit 200 patients within a 7y recruitment period (2014-2021). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetic Nephropathy
How many people
200 participants
Where
1 siteSwitzerland
Study dates
1 Jan 2014to 1 Jan 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Individuals with type 2 diabetes and CKD stage 1-5

Who may be able to join

  • Type 2 diabetes
  • eGFR <60ml/min or albumine/creatinine ratio >3mg/mmol
  • Can understand french and has signed the consent form.

Who cannot join

  • Age < 18y
  • Another cause of nephropathy (excluding hypertensive nephropathy, obese related nephropathy)

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Canton of Vaud, 1011

Other trials in Switzerland

About this study

With our SWIDINEP cohort, we propose to explore the relationship between vascular risk markers and renal function decline in CKD stage 1-5. In order to realize these goals, we intend to recruit 200 patients within a 7y recruitment period (2014-2021). Recruitment is done in the nephrology and diabetes ambulatory clinics in the CHUV at Lausanne. Each eligible patient is identified and whether he/she can be proposed the study is discussed with the physician in charge of the patient. Once the patient is informed and has signed the consent form, he/she is examined in the Service of Nephrology at baseline, 2y and 5y.

Read the detailed description

Serum, plasma, and fresh urine samples as well as whole blood (buffy coat for DNA extraction and genotyping) are stored at -80°C in a local biobank according to the latest guidelines of the Académie Suisse des Sciences Médicales (ASSM).

The vascular phenotype includes:

  • 24h ABPM with the examination of diurnal variations of blood pressure, pulse pressure and heart rate. Central pulse pressure is also calculated based on the pulse wave analysis providing information on stroke volume, central BP, aortic stiffness and arterial wave reflection. It increases with age and could expose glomerular capillaries to damage. It has been independently related to proteinuria.
  • Arterial stiffness is assessed non-invasively with the commercially available Sphygmocor system (Version 8.0, At Cor Medical, Sydney, Australia) using applanation tonometry to measure carotid-femoral pulse wave velocity (PWV) and carotid and radial augmentation indexes. Pulse wave velocity is a strong surrogate for carotid-femoral arterial stiffness. Generally around 3-4m/s in the young population it increases with age. A high PWV brings to a greater transmission of pulsating pressure to the renal microcirculation and is associated with accelerated eGFR decline. Recently, a study has described its independent relationship with cardio-vascular mortality in CKD stage 2-4. Patients with a PWV at least at 10m/s had a HR for mortality of 5. Carotid and radial augmentation indexes measure the difference between the second and first systolic peak of the aortic wave and is expressed as a percentage of pulse pressure. They increase with age and have been correlated with eGFR and albuminuria.
  • Carotid ultrasound is performed to assess carotid intima-media thickness. Carotid-intima media thickness is a direct measurement of atherosclerosis and can help stratify patients at CV risk. It has been associated with eGFR decline.
  • Participants undergo a renal ultrasound including renal resistance index measurements as marker of intrarenal vascular disease according to a pre-specified protocol used previously in other local cohorts by the same experienced operator (PD Dr Menno Pruijm). The assessment of the intrarenal vessels is made by duplex Doppler sonography on 3 segmental arteries (superior, middle, and inferior) in each kidney. The values are then averaged to obtain the mean value for each participant. Renal resistive index (RRI) is calculated as [(peak-systolic velocity - end-diastolic velocity)/peak-systolic velocity]. The Service of nephrology has performed an important study providing reference values in a population with normal renal ultrasounds. Renal resistive index has been associated with eGFR decline. Besides, all participants are screened for underlying renal artery stenosis based on well established intrarenal Doppler criteria. The presence of other renal structural abnormalities (renal cysts, tumors, calcifications and/or hydronephrosis) is also assessed. Finally, the bladder area is systematically visualized, as well as the prostatic gland in men.
  • Subjects undergo ocular examination, including best-corrected visual acuity (BCVA), slit lamp biomicroscopic exam, measurement of intraocular pressure with a non-contact tonometer and fundus examination. Choroidal thickness is measured by the EDI-OCT technique. The subfoveal choroidal thickness is measured at macular fovea from the outer portion of the hyperreflective line corresponding to the RPE to the hyporeflective line or margin corresponding to the sclerochoroidal interface. Central macular retinal thickness is determined automatically in all eyes. There are emerging data regarding the relationship of choroidal circulation and various systemic and ocular diseases. The choroid is highly vascularized tissue that supplies blood to the outer retina, including the retinal pigment epithelium (RPE) cells and photoreceptors, especially in the foveal region where there is no retinal vasculature. The choroid plays a crucial part in the physiopathology of many retinal diseases. Details of the choroidal circulation remained largely unknown due to poor resolution and reproducibility of previous choroidal imaging techniques. Imaging of the choroid was dramatically improved with the development of spectral domain optical coherence tomography and was further augmented with the advent of enhanced depth imaging. The relation between renal dysfunction and impaired ocular microcirculation remains unclear, especially in early-stage diabetes. It's been reported that the blood flow in the retinal arterioles is decreased in patients with type 2 diabetes with chronic kidney disease. Though, data on the relationship between choroidal thickness and diabetic nephropathy are sparse. As far as we are aware today, there is only one study that evaluated choroidal thickness alterations in diabetic nephropathy patients with early or no diabetic retinopathy. More precisely the subfoveal, temporal and nasal choroidal thickness was noted to be thinner in patients with diabetic nephropathy patients compared with non- diabetic nephropathy patients and normal subjects.

Quality of life questionnaires: A number of studies have shown that as kidney function decreases, disease burden increases, with lower health-related quality of life (HRQoL) for patients with late stages of chronic kidney disease. However, few studies have looked into HRQoL and its determinants in the specific population of diabetic patients with kidney disease. Assessing HRQoL and its determinants is important in chronic care as studies have shown that patients with higher HRQoL function better within the healthcare system and perform more health-promoting activities. HRQoL is assessed at baseline in patients enrolled in the cohort. The impact of baseline HRQoL on renal function decline will be analysed.

Medical subject headings
Diabetic Nephropathies

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. estimated GFR decline ml/min/y

    estimated GFR will be based on the creatinine based CKD-EPI formula

    Measured: 2-5 years

Secondary outcomes (8)
  1. 24 hour blood pressure measurements (mmHg) and eGFR decline (ml/min/y)

    Relationship of 24h blood pressure diurnal pattern and eGFR decline

    Measured: 2-5 years

  2. Vascular markers (Pulse wave velocity (m/s); Carotid and radial augmentation indexes (%); intima media thickness (mm)) and eGFR decline (ml/min/y)

    Relationship of baseline vascular markers and eGFR decline

    Measured: 2-5 years

  3. Kidney volume (cm3) and resistance index and eGFR decline (ml/min/y)

    Relationship of renal volume/resistance index and eGFR decline

    Measured: 2-5y

  4. Biochemical parameters and eGFR decline (ml/min/y)

    Relationship of baseline biochemical biomarkers and eGFR decline

    Measured: 2-5y

  5. Genetic markers and eGFR decline (ml/min/y)

    Relationship of genetic markers and eGFR decline

    Measured: 2-5y

  6. Choroidal thickness (microm) and eGFR decline (ml/min/y)

    Relationship of baseline choroidal thickness and eGFR decline

    Measured: 2-5y

  7. Generic health-related quality of life baseline measures, CKD stage, and eGFR decline.

    The influence of CKD stage and eGFR decline on generic and diabetes-specific health related quality of life questionnaires.

    Measured: 2-5y

  8. Diabetes-specific health-related quality of life baseline measures, CKD stage, and eGFR decline.

    The influence of CKD stage and eGFR decline on generic and diabetes-specific health related quality of life questionnaires.

    Measured: 2-5y

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2018
  2. Study start1 Jan 2014
  3. Primary completion1 Jan 2022 (estimated)
  4. Study completion1 Jan 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03407989
Sponsor's protocol ID
CER 43/12
Acronym
SWIDINEP
Status last verified
Aug 2021
First submitted
9 Jan 2018
Last updated
5 Aug 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetic Nephropathy, run by Centre Hospitalier Universitaire Vaudois at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

estimated GFR decline ml/min/y (time frame: 2-5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in